Bio/Pharma News

Jan 18, 2018
By Pharmaceutical Technology Editors
The company is developing a pipeline of combination therapies using its patented polymer-based matrix delivery system, known as TAOS (targeted orchestrated signalling matrix).
Jan 12, 2018
By Pharmaceutical Technology Editors
The acquisition, valued at EUR 520 million (US$631 million), would expand Takeda’s late-stage pipeline in gastroenterology and would extend an already existing collaboration between the two companies.
Jan 11, 2018
By Pharmaceutical Technology Editors
Athenex is moving forward with the construction of a new 320,000-square-foot pharmaceutical manufacturing facility in Dunkirk, NY, and has hired the German engineering firm, M+W, to design and construct the facility.
Jan 11, 2018
By Pharmaceutical Technology Editors
A Takeda and Denali collaboration includes three named programs for treating Alzheimer’s disease and other neurodegenerative diseases, using Denali’s antibody transport vehicle (ATV) technology to enhance blood-brain barrier penetration.
Jan 09, 2018
By Pharmaceutical Technology Editors
The company announced 15 new collaborations focused on addressing unmet medical needs, including using artificial intelligence in the early detection of Alzheimer’s disease, saliva testing for throat cancers, and using the microbiome to treat sleep disorders.
Jan 05, 2018
By Pharmaceutical Technology Editors
The companies aim to discover and develop locked nucleic acid oligonucleotides as orally available therapies for treating inflammatory bowel diseases.
Jan 05, 2018
By Pharmaceutical Technology Editors
The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.
Dec 28, 2017
By Pharmaceutical Technology Editors
Roche has agreed to acquire Ignyta, an oncology company specializing in precision medicines, in an all-cash transaction valued at $1.7 billion.
Dec 28, 2017
By Pharmaceutical Technology Editors
Mallinckrodt has agreed to acquire biopharmaceutical company Sucampo Pharmaceuticals for $18 per share, or a transaction value of approximately $1.2 billion.
Dec 20, 2017
By Pharmaceutical Technology Editors
FDA has approved a new gene therapy for treating patients born with a rare, inherited vision loss.
native1_300x100
lorem ipsum